Modulation of the reninangiotensinaldosterone system in sepsis: A new therapeutic approach?

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 1, 2010, Pages 11-20

  Salgado, Diamantino Ribeiro ^a,b   Rocco, Jos Rodolfo ^a   Silva, Elizer ^c,d   Vincent, Jean Louis ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b ERASME HOSPITAL   (Belgium)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiotensin; Angiotensin converting enzyme; Rennin; Sepsis

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR;

BLOOD PRESSURE; DRUG TARGETING; HEART OUTPUT; HUMAN; HYPOTENSION; INFLAMMATION; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEPSIS; SEPTIC SHOCK; VASODILATATION; DRUG EFFECT; HEMODYNAMICS; METABOLISM; MICROCIRCULATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEMODYNAMICS; HUMANS; MICROCIRCULATION; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; SEPSIS;

EID: 72549109523     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903460332     Document Type: Review

References (92)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554
2. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112:235-243
3. Rolih CA, Ober KP. The endocrine response to critical illness. Med Clin North Am 1995;79:211-224
4. Benedict CR, Rose JA. Arterial norepinephrine changes in patients with septic shock. Circ Shock 1992;38:165-172
5. Marik PE, Zaloga GP. Adrenal insufficiency in the critically ill: a new look at an old problem. Chest 2002;122:1784-1796
6. Annane D, Sebille V, Troche G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283:1038-1045
7. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-1377
8. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004;351:159-169
9. Lavoie JL, Sigmund CD. Minireview: overview of the renin-angiotensin system- an endocrine and paracrine system. Endocrinology 2003;144:2179-2183
10. Re RN. Tissue renin angiotensin systems. Med Clin North Am 2004;88:19-38
11. du Cheyron D, Lesage A, Daubin C, et al. Hyperreninemic hypoaldosteronism: a possible etiological factor of septic shock-induced acute renal failure. Intensive Care Med 2003;29:1703-1709
12. Boldt J, Papsdorf M, Kumle B, et al. Influence of angiotensin-converting enzyme inhibitor enalaprilat on endothelial-derived substances in the critically ill. Crit Care Med 1998;26:1663-1670
13. Bucher M, Ittner KP, Hobbhahn J, et al. Downregulation of angiotensin II type 1 receptors during sepsis. Hypertension 2001;38:177-182
14. Cumming AD, Driedger AA, McDonald JW, et al. Vasoactive hormones in the renal response to systemic sepsis. Am J Kidney Dis 1988;11:23-32
15. Dunn CW, Horton JW. Role of angiotensin II in neonatal sepsis. Circ Shock 1993;40:144-150
16. Hilgenfeldt U, Kienapfel G, Kellermann W, et al. Renin-angiotensin system in sepsis. Clin Exp Hypertens A 1987;9:1493-1504
17. Tamion F, Cam-Duchez V, Menard JF, et al. Erythropoietin and renin as biological markers in critically ill patients. Crit Care 2004;8:R328-35
18. Wray GM, Coakley JH. Severe septic shock unresponsive to noradrenaline. Lancet 1995;346:1604
19. Adembri C, Kastamoniti E, Bertolozzi I, et al. Pulmonary injury follows systemic inflammatory reaction in infrarenal aortic surgery. Crit Care Med 2004;32:1170-1177
20. Skott O, Jensen BL. Cellular and intrarenal control of renin secretion. Clin Sci (Lond) 1993;84:1-10
21. Nushiro N, Ito S, Carretero OA. Renin release from microdissected superficial, midcortical, and juxtamedullary afferent arterioles in rabbits. Kidney Int 1990;38:426-431
22. Almeida WS, Maciel TT, Di Marco GS, et al. Escherichia coli lipopolysaccharide inhibits renin activity in human mesangial cells. Kidney Int 2006;69:974-980
23. Naftilan AJ, Zuo WM, Inglefinger J, et al. Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. J Clin Invest 1991;87:1300-1311
24. Boehm M, Nabel EG. Angiotensin-converting enzyme 2-a new cardiac regulator. N Engl J Med 2002;347:1795-1797
25. Ihara M, Urata H, Kinoshita A, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999;33:1399-1405
26. Johnston CI. Franz volhard lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens Suppl 1992;10:S13-26
27. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-1346
28. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87:E1-9
29. Shariat-Madar Z, Schmaier AH. The plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis. J Endotoxin Res 2004;10:3-13
30. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-454
31. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002;417:822-828
32. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005;436:112-116
33. Zhuo JL, Li XC. Novel roles of intracrine angiotensin II and signalling mechanisms in kidney cells. J Renin Angiotensin Aldosterone Syst 2007;8:23-33
34. Denton KM, Fennessy PA, Alcorn D, Anderson WP. Morphometric analysis of the actions of angiotensin II on renal arterioles and glomeruli. Am J Physiol 1992;262:F367-7235.
35. Ichikawi I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 1991;40:583-596
36. Verrey F. Sodium reabsorption in aldosterone-sensitive distal nephron: news and contributions from genetically engineered animals. Curr Opin Nephrol Hypertens 2001;10:39-47
37. Funder JW. Non-genomic actions of aldosterone: role in hypertension. Curr Opin Nephrol Hypertens 2001;10:227-230
38. Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003;35:881-900
39. Pastore L, Tessitore A, Martinotti S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999;100:1646-1652
40. Miyoshi M, Nagata K, Imoto T, et al. ANG II is involved in the LPS-induced production of proinflammatory cytokines in dehydrated rats. Am J Physiol Regul Integr Comp Physiol 2003;284:R1092-7
41. Ruiz-Ortega M, Ruperez M, Lorenzo O, et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 2002;62:S12-22
42. Chai SY, Fernando R, Peck G, et al. The angiotensin IV/AT4 receptor. Cell Mol Life Sci 2004;61:2728-2737
43. Dielis AW, Smid M, Spronk HM, et al. Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients. J Thromb Haemost 2007;5:1509-1515
44. Higuchi S, Ohtsu H, Suzuki H, et al. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 2007;112:417-428
45. de Cavanagh EM, Toblli JE, Ferder L, et al. Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine. Am J Physiol Regul Integr Comp Physiol 2006;290:R1616-25
46. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008;102:488-496
47. Monteiro P, Duarte AI, Goncalves LM, Providencia LA. Valsartan improves mitochondrial function in hearts submitted to acute ischemia. Eur J Pharmacol 2005;518:158-164
48. Ballinger SW. Mitochondrial dysfunction in cardiovascular disease. Free Radic Biol Med 2005;38:1278-1295
49. Bulteau AL, Szweda LI, Friguet B. Mitochondrial protein oxidation and degradation in response to oxidative stress and aging. Exp Gerontol 2006;41:653-657 (Pubitemid 43866355)
50. Yasuda S, Lew WY. Angiotensin II exacerbates lipopolysaccharide-induced contractile depression in rabbit cardiac myocytes. Am J Physiol 1999;276:H1442-9
51. Re RN. On the biological actions of intracellular angiotensin. Hypertension 2000;35:1189-1190
52. Duprez DA. Role of the renin- angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006;24:983-991
53. Kurdi M, De Mello WC, Booz GW. Working outside the system: an update on the unconventional behavior of the renin- angiotensin system components. Int J Biochem Cell Biol 2005;37:1357-1367
54. Inagami T, Kambayashi Y, Ichiki T, et al. Angiotensin receptors: molecular biology and signalling. Clin Exp Pharmacol Physiol 1999;26:544-549
55. Liu FY, Cogan MG. Role of protein kinase C in proximal bicarbonate absorption and angiotensin signaling. Am J Physiol 1990;258:F927-33
56. Lund DD, Brooks RM, Faraci FM, Heistad DD. Role of angiotensin II in endothelial dysfunction induced by lipopolysaccharide in mice. Am J Physiol Heart Circ Physiol 2007;293:H3726-31
57. Wolf G, Wenzel U, Burns KD, et al. Angiotensin II activates nuclear transcription factor-kB through AT1 and AT2 receptors. Kidney Int 2002;61:1986-1995
58. Tsuzuki S, Matoba T, Eguchi S, Inagami T. Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase. Hypertension 1996;28:916-918
59. Aneman A, Bengtsson J, Snygg J, et al. Differentiation of the peptidergic vasoregulatory response to standardized splanchnic hypoperfusion by acute hypovolaemia or sepsis in anaesthetized pigs. Acta Physiol Scand 1999;166:293-300
60. Laesser M, Oi Y, Ewert S, et al. The angiotensin II receptor blocker candesartan improves survival and mesenteric perfusion in an acute porcine endotoxin model. Acta Anaesthesiol Scand 2004;48:198-204
61. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-1654
62. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-1477
63. Fox GA, Paterson NA, McCormack DG. Effect of inhibition of NO synthase on vascular reactivity in a rat model of hyperdynamic sepsis. Am J Physiol 1994;267:H1377-82
64. Bucher M, Hobbhahn J, Kurtz A. Nitric oxide-dependent down-regulation of angiotensin II type 2 receptors during experimental sepsis. Crit Care Med 2001;29:1750-1755
65. Martineau D, Lamouche S, Briand R, Yamaguchi N. Functional involvement of angiotensin AT2 receptor in adrenal catecholamine secretion in vivo. Can J Physiol Pharmacol 1999;77:367-374 (Pubitemid 30339564)
66. Lange M, Morelli A, Ertmer C, et al. Role of adenosine triphosphate-sensitive potassium channel inhibition in shock states: physiology and clinical implications. Shock 2007;28:394-400
67. Dong LW, Chang YZ, Tong LJ, et al. Role of regulatory peptide in pathogenesis of shock. Sci China B 1994;37:162-968.
68. Newton CR, Curran B, Victorino GP. Angiotensin II type 1 receptor activation increases microvascular permeability via a calcium dependent process. J Surg Res 2005;123:33-39
69. Wang W, Falk SA, Jittikanont S, et al. Protective effect of renal denervation on normotensive endotoxemia-induced acute renal failure in mice. Am J Physiol Renal Physiol 2002;283:F583-7
70. Cumming AD, Kline R, Linton AL. Association between renal and sympathetic responses to nonhypotensive systemic sepsis. Crit Care Med 1988;16:1132-1137
71. Ronco C, Kellum JA, Bellomo R, House AA. Potential interventions in sepsis-related acute kidney injury. Clin J Am Soc Nephrol 2008;3:531-544
72. Kikeri D, Pennell JP, Hwang KH, et al. Endotoxemic acute renal failure in awake rats. Am J Physiol 1986;250:F1098-106
73. Nitescu N, Grimberg E, Guron G. Low-dose candesartan improves renal blood flow and kidney oxygen tension in rats with endotoxin-induced acute kidney dysfunction. Shock 2008;30:166-172
74. Gupta A, Rhodes GJ, Berg DT, et al. Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2. Am J Physiol Renal Physiol 2007;293:F245-54
75. Findling JW, Waters VO, Raff H. The dissociation of renin and aldosterone during critical illness. J Clin Endocrinol Metab 1987;64:592-595
76. Marshall RP, Webb S, Bellingan GJ, et al. Angiotensin converting enzyme insertion/ deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002;166:646-650
77. Yao S, Feng D, Wu Q, et al. Losartan attenuates ventilator-induced lung injury. J Surg Res 2008;145:25-32
78. Shen L, Mo H, Cai L, et al. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kB and mitogen-activated protein kinases. Shock 2009;31:500-506
79. Hagiwara S, Iwasaka H, Hidaka S, et al. Antagonist of the type-1 ANG II receptor prevents against LPS-induced septic shock in rats. Intensive Care Med 2009;35:1471-1478
80. Fischer S, Maclean AA, Liu M, et al. Inhibition of angiotensin-converting enzyme by captopril: a novel approach to reduce ischemia-reperfusion injury after lung transplantation. J Thorac Cardiovasc Surg 2000;120:573-580
81. Richardson MA, Gupta A, O'Brien LA, et al. Treatment of sepsis-induced acquired protein C deficiency reverses Angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response. J Pharmacol Exp Ther 2008;325:17-26
82. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 1993;290 (Pt 1):33-40
83. Jerng JS, Yu CJ, Wang HC, et al. Polymorphism of the angiotensinconverting enzyme gene affects the outcome of acute respiratory distress syndrome. Crit Care Med 2006;34:1001-1006
84. Villar J, Flores C, Perez-Mendez L, et al. Angiotensin-converting enzyme insertion/ deletion polymorphism is not associated with susceptibility and outcome in sepsis and acute respiratory distress syndrome. Intensive Care Med 2008;34:488-495
85. Spronk PE, Ince C, Gardien MJ, et al. Nitroglycerin in septic shock after intravascular volume resuscitation. Lancet 2002;360:1395-1396
86. De Backer D, Creteur J, Preiser JC, et al. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002;166:98-104
87. Yunge M, Petros A. Angiotensin for septic shock unresponsive to noradrenaline. Arch Dis Child 2000;82:388-389
88. De Backer D, Creteur J, Dubois MJ, et al. Microvascular alterations in patients with acute severe heart failure and cardiogenic shock. Am Heart J 2004;147:91-99
89. Kan H, Finkel MS, Johnson LA. Fighting fire with fire. Crit Care Med 1998;26:1628-1629
90. Yao S, Feng D, Wu Q, et al. Losartan attenuates ventilator-induced lung injury. J Surg Res 2008;145:25-32
91. Hagiwara S, Iwasaka H, Matumoto S, et al. Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models. Crit Care Med 2009;37:626-633
92. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008;31:611-617